Learning Hub

Dissemination and communication team Kristina Leipuviene SmartSol SIA Position Project manager What is your role in iPROLEPSIS? Dissemination/Communication lead What are your main activities in the project? Leading and planning communication and dissemination activities. SmartSol team also supports networking and clustering with stakeholders. What is your motivation? As leaders of WP6, SmartSol aims to increase awareness of iPROLEPSIS and make it accessible to everyone. We focus on sharing information, raising awareness about psoriatic arthritis, and making a lasting impact through thoughtful planning and engagement with the public. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

< BACK iPROLEPSIS: updates on user research and co-creation Oct 17, 2023 Co-creation sessions for advancing the development of the mIPROLEPSIS app iPROLEPSIS active engagement with users through ongoing co-creation sessions helps to advance the development of the mIPROLEPSIS app, scheduled for delivery before January 2024. In October 2023, the project partner Erasmus MC (EMC) conducted a co-creation session with patient partners to assess the User Interface (UI) of the PDPID-app. The focus was on improving usability, ensuring users’ understanding of expectations and enhancing users’ engagement to minimise missing data. The project partner FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA), is also developing storyboards for the personalised gaming suite . Three co-creation sessions were conducted: one with healthcare professionals and two with patient partners. Project partners The Centre for Research and Technology Hellas (CERTH) and FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA), in collaboration with the clinical partners, worked on identifying movements for the video analysis that will be included in the iPROLEPSIS-PDPID study. Multiple hand gestures and fullbody movements were identified for further assessment. Main points: mIPROLEPSIS App’s general looks and UI were approved by the patient partners; Despite being a data-collection app for research purposes, patients emphasise the significance of reviewing their own data entries; Participants noted a need for enhanced visual cues regarding specific activities in the app. Main points: Personalised gaming suite Smart games meant for disease management need to be highly tailored to the capabilities of the patients; Patients view gaming as a form of relaxation, emphasising the importance of stress-free design; Patient partners expressed interest in the proposed gaming categories. 1/0 PREVIOUS NEXT

< BACK Advancing Digital Health Solutions: Updates on User Research and Co-Creation Nov 20, 2023 Navigating the Development of PDPID-App, Insights from Co-Creation Sessions Updates on user research and co-creation The current status of user research and co-creation involves a dedicated focus on advancing the development of the PDPID-app , scheduled for delivery before January 2023. In early October 2023, Erasmus MC ( EMC) conducted a co-creation session with patient partners to assess the general looks and feel of the User Interface (UI) and identify points to improve the app's usability. In apps used for medical data collection, it is of utmost importance that users know what is expected of them. Furthermore, users should be engaged with the app to a level that minimises missing data. Following this, bi-weekly meetings with patient partners were established to maintain alignment with their ideas. Furthermore, project partner FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA) is developing storyboards for the personalised gaming suite . Three co-creation sessions have been executed: one with healthcare professionals and two with patient partners. Additionally, project partners The Centre for Research and Technology Hellas (CERTH) and FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA) have been working with the clinical partners to identify movements for the video analysis tasks that will be included in the iPROLEPSIS-PDPID study. Multiple hand gestures and full-body movements have been identified for further assessment. Key take-away messages The development of the Digital health tools is still at an early stage. However, several take-away messages from the discussions about the PDPID app are : The general looks and UI of the miPROLEPSIS app have been approved by the patient partners. Even though the PDPID-app is a data-collection app for research purposes, patients find it of utmost importance that they can review their own data entries. Participants indicated that the app needs to improve its’ visual cues of when they need to perform certain activities. Take-away messages from the discussions about personalised gaming suite development: Smart games meant for disease management should be highly tailored to the capabilities of the patients. Gaming is for patients a way of relaxation, any game designed should not incorporate any stressful factors. Patient partners expressed interest in the proposed gaming categories. Future steps Future steps involve initiating a round of user testing for the PDPID version of the miPROLEPSIS app to validate designs with patients not involved in the development process. Subsequently, attention will shift to developing recommendation systems for physical activity and diet, incorporating insights from experts in the field (occupational therapists, physical therapists & nutritionists) and patients themselves. For the personalised gaming suite, the completion of the storyboard is planned for the end of December 2023, when the development of the first prototypes will follow. mIPROLEPSIS app.png mIPROLEPSIS app.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 7 Jan 28, 2025 Latest News from iPROLEPSIS Welcome to the 7th edition of the iPROLEPSIS newsletter. In this edition, we share the latest updates and progress from our project, including new developments, recent publications, and reflections on key events. iPROLEPSIS project newsletter_Jan 2025_Issue No. 7 .pdf Download PDF • 5.60MB 1/1 PREVIOUS NEXT

< BACK Designing Exergames for Psoriatic Arthritis: The Spy and Zen Forest Paradigms Feb 4, 2026 New iPROLEPSIS publication presents the co-design of exergames to support physical activity and rehabilitation in psoriatic arthritis A new publication from the iPROLEPSIS project has been published in the proceedings of the 2025 IEEE International Conference on E-health Networking, Application & Services (HealthCom) . Psoriatic arthritis (PsA) is a rheumatic disease affecting the skin and joints and is commonly associated with stiffness, impaired mobility, and chronic pain. In addition to biological treatments, physiotherapy and exercise are often recommended to improve range of motion and physical function. However, low adherence, high costs, and limited engagement frequently reduce the effectiveness of these interventions. The paper presents the design of two exergames – The Spy and Zen Forest – developed as accessible digital tools to complement traditional rehabilitation approaches. Exergames embed therapeutic movements into game mechanics, supporting motivation and consistency in physical activity. Both games were co-designed with 29 experts , including patients with psoriatic arthritis, clinicians, researchers, and technical stakeholders, to ensure alignment with clinical goals, patient needs, and safe physical engagement. In The Spy , players complete physically engaging missions designed to stimulate dynamic body movement and support coordination, mobility, balance, strength, and flexibility. Zen Forest focuses on slow, calm stretching routines inspired by Pilates and Yoga, promoting flexibility, relaxation, and body awareness. Together, the exergames aim to support personalised activity routines and enable clinicians to monitor progress and recommend tailored interventions. Read the full publication: https://zenodo.org/records/18468928 iPROLEPSIS_Zen and Spy.png iPROLEPSIS_Zen and Spy.png 1/1 PREVIOUS NEXT

< BACK ChatGPT in Nutrition: Trends, Challenges and Future Directions Jun 27, 2024 Exploring the Role of AI in Shaping the Future of Personalised Nutrition Introducing our latest iPROLEPSIS publication, "ChatGPT in Nutrition: Trends, Challenges, and Future Directions" , presented at PETRA 2024. This study explores the evolving role of AI in personalized nutrition. Abstract: A healthy and balanced diet is of paramount importance to the physical and psychological well-being of an individual, since unhealthy dietary choices have been linked with the occurrence of non-communicable diseases. Recent technological advances has led to the development of large language models, such as ChatGPT that has been widely adopted as a convenient tool for creating meal plans and obtaining nutritional information. This work aims to provide a thorough review of the scientific work performed so far regarding the use of ChatGPT in the field of nutrition. In this survey, the advantages and limitations of ChatGPT in different aspects of nutrition are pinpointed, while the challenges from the use of ChatGPT in nutrition are identified and discussed. Future research directions are also proposed to assist researchers towards the development of more effective nutrition recommendation systems. Read the full publication: https://zenodo.org/records/13142880 ChatGPT in Nutrition .pdf Download PDF • 620KB 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Website Goes Live Mar 26, 2023 The website of the iPROLEPSIS project is finalised and available online. The website of the iPROLEPSIS project is finalised and available online. The website presents the key facts and figures about the project, and will be frequently updated about the project results, events, and key plans. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK The miPROLEPSIS App Now Available for Android Devices on Google Play Store Sep 30, 2024 A data collection tool for the iPROLEPSIS-PDPID study now on Android As of 30 September 2024, the miPROLEPSIS app is available for Android devices on the Google Play Store. The miPROLEPSIS PDPID Study application functions as a data collection tool, utilized during the PDPID study, in order to produce datasets used for model generation and training. The app utilises both continuous and unobtrusive data collection (via bluetooth) from wearable devices, as well as user interactions (questionnaires, reporting etc). miPROLEPSIS - Apps on Google Play 1/1 PREVIOUS NEXT

< BACK Workshop at PETRA 2024: Advancing Personalised Health Through Multimodal Sensing and Innovative Environments Jan 25, 2024 Exploring the Future of Healthcare: AI-PROGNOSIS and iPROLEPSIS Projects Collaborate for Workshop on Human Health, Habits, and Behavior The workshop "AGENT - MultimodAl SiGnal Sensing/Analysis, Innovative Interactive Environments, and PersoNalized Behavioral Modeling for Improving QualiTy-of-Life" has been accepted in PETRA 2024! The workshop will be organised by the Centre for Research & Technology Hellas , Aristotle University of Thessaloniki , and Faculdade de Motricidade Humana in cooperation with the AI-PROGNOSIS and iPROLEPSIS projects. More info about the workshop: http://www.petrae.org/workshops/AGENT.html AI-PROGNOSIS is a Horizon Europe-funded project developing Artificial intelligence-based solutions for #Parkinson 's disease risk assessment and prognosis. iPROLEPSIS is a Horizon Europe-funded project developing a novel personalised digital care ecosystem for people with #Psoriatic #arthritis . The workshop aims to attract an interdisciplinary group of researchers involved in research related to early detection, assessment and monitoring of human health, habits and behaviour. The workshop will focus on novel technologies applied in real or virtual environments and aim to enhance the quality of daily living, especially for people with disabilities or patients suffering from chronic conditions. About PETRA 2024: PETRA (PErvasive Technologies Related to Assistive Environments) is a premier interdisciplinary conference focusing on computational and engineering approaches to enhance human performance and improve the quality of life. Join us in exploring the latest advancements in assistive technologies across various settings. More info: http://www.petrae.org/index.html Looking forward to an enriching exchange of ideas and knowledge at PETRA 2024! Banner1-2024.png Banner1-2024.png 1/1 PREVIOUS NEXT

< BACK Patient Voices in Research: Elaine’s Das Cheppo Journey with iPROLEPSIS Mar 4, 2025 A Patient’s Perspective: Elaine’s Journey with iPROLEPSIS Elaine Das Cheppo has been living with psoriatic arthritis for 25 years . Like many others, her diagnosis was delayed, making treatment more challenging in the early years. When her rheumatologist asked if she would like to take part in the iPROLEPSIS project , she did not hesitate. "I struggled in the beginning to understand why I was experiencing so much joint pain. By participating in this study, I hope to help future generations get a diagnosis faster than I did." The Role of Patient Partners in iPROLEPSIS Elaine is a patient partner in iPROLEPSIS, working alongside researchers to improve psoriatic arthritis care. She finds the co-creation sessions particularly insightful, offering her a behind-the-scenes look at how digital health solutions are developed. "It’s interesting to see how new technology is being used to improve diagnosis and treatment. These innovations could help people avoid unnecessary doctor visits and manage their condition more effectively." A Renewed Sense of Purpose For Elaine, being part of iPROLEPSIS is not just about contributing to research—it’s also about personal fulfillment . "For someone who has been retired for quite some time, it’s rewarding to have a new goal and interest in life. Being part of this project gives me a way to make a difference." Watch Elaine’s full story here: https://www.youtube.com/watch?v=BB0udK7B57w 1/1 PREVIOUS NEXT

Welcome to our collaborative initiative, a dedicated networking subpage showcasing the synergistic efforts of innovative projects. iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being. By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 CARE-IN-HEALTH Cardiovascular REsolution of INflammation to promote HEALTH WEBSITE Cardiovascular diseases (CVD) are the leading cause of mortality in Europe (1.9 million of annual deaths). CVD are significant public health challenge, accounting for €200 billion in economic burden annually in Europe. Lipid-mediated chronic inflammation and particularly the failure in the resolution of the inflammation, is a particular critical risk factor for the transition from health to CVD. CARE-IN-HEALTH addresses this by aiming to identify the pathways involved in the resolution of the lipid-mediated inflammation to prevent and reverse inflammation and therefore CVD. The interdisciplinary consortium will collect and integrate epidemiological, multi-omics, and immune data to create the CARE-IN-HEALTH Atlas, which will be openly accessible to the scientific community. Such a knowledge base will allow to systematically identify and validate individual’s critical immune pathways. A CARE-IN-HEALTH MCDSS (multi-criteria decision support system) will guide healthcare professionals to design personalised CVD prevention strategies. The CARE-IN-HEALTH BIOSENSOR will monitor inflammation resolution for citizens. CARE-IN-HEALTH will demonstrate proof-of-concept for an appropriate lipid intake as dietary intervention and specifically, for the use of vegetal omega-3 fatty acid sources as substrates for immunomodulatory lipid mediators and resolution of inflammation. All this is based on the results of a proof-of-concept clinical trial. GlycanTrigger Glycans as master triggers of health to intestinal inflammation transition WEBSITE GLYCANTRIGGER - Glycans as master triggers of health to intestinal inflammation transition. The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with Crohn’s Disease that will be translated into improved disease prediction and prevention. The project will address how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms but also systemic mechanisms, involving the novel concept of glycan mimicry as an early trigger of the health-to-inflammation transition. The long-term goal of this project is to unlock a new checkpoint that regulates the transition to chronic inflammation, aiming to figure out how to turn off this process by developing novel preventive intervention strategies. halt-RONIN Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies. Downolad PDF to read more. WEBSITE NAFL (non-alcoholic fatty liver) is the most widespread subtype of NAFLD, a highly prevalent inflammation-related disease, characterized by steatosis, relatively benign and reversible condition, which can progress to the more serious progressive stage of non-alcoholic steatohepatitis (NASH), in which steatosis is accompained by lipotoxicity, mitochondrial dysfunction and a high state of inflammation and fibrosis. IMMEDIATE Imminent Disease Prediction and Prevention at the Environment Host Interface WEBSITE The EU-funded research project IMMEDIATE strives to identify individual biomarkers of risk and resilience against chronic inflammation by investigating the diet-microbiome-metabolite-immune axis. This complex interaction refers to how an individual's diet, gut microbiota, metabolites, and immune system can influence their health. IMMEDIATE will use cutting-edge technologies and clinical and metadata from large observational cohort studies to identify pre-disease stages and further our understanding of the mechanisms and molecular pathways underpinning non-communicable diseases. Furthermore, a proof-of-concept study on healthcare professionals will be conducted to test the effectiveness of a probiotic intervention and ultimately develop mobile apps designed to offer personalized lifestyle recommendations and empower citizens to manage their own health proactively. INITIALISE Inflammation in human early life: targeting impacts on life-course health WEBSITE INITIALISE (Inflammation in human early life: targeting impacts on life-course health) is an EU funded project that aims to elucidate how exposures and genome impact gut microbiome, host immune system and metabolism, and how the interplay of these factors impact life-course health.  INITIALISE aims to define the role of the maturation of the immune system as a mediator between exposures and life-course health. INTERCEPT-T2D Early Interception of Inflammatory-mediated Type 2 Diabetes WEBSITE Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycaemia and risk of chronic complications such as stroke, heart attacks, nephropathy and retinopathy are so far difficult to predict. Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. The EU-funded INTERCEPT-T2D project will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. Moreover, the project will help deliver optimal treatments tailored to patient needs and conduct a clinical trial to evaluate the efficacy of anti-inflammatory strategies. miGut-Health Personalised blueprint intestinal health WEBSITE The miGut-Health project is an EU-funded initiative that is developing novel strategies to predict and prevent inflammatory bowel disease (IBD). miGut-Health aims to create personalised patient engagement strategies for predicting and monitoring preclinical IBD by focusing on the transitory phase from health to disease. The overarching goal is to provide strategies for early disease prediction, prevention and gut health improvement for people affected by IBD, high-risk individuals and citizens. AIDA An Artificially Intelligent Diagnostic Assistant for gastric inflammation WEBSITE Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook. Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Aida aims to do just that. It helps researchers understand the mechanisms that trigger gastric oncogenesis, helps clinicians diagnose precancerous inflammation at the earliest possible stage, suggests personalised therapeutic strategies for treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This places Aida squarely on Europe’s agenda of ‘Staying healthy in a rapidly changing society’. Aida unites some of Europe’s leading authorities in the field of gastric inflammation, gastric cancer, leading AI and machine learning experts, experts on data governance and privacy, representatives of the public administration and patient advocates. Aida also has strong ties with the industry. After the project, the results will live on in a foundation that acts as a transnational focal point for chronic gastric inflammation — and GC in general. We hope that the solid, inclusive design principles of Aida, its societal relevance and its durability will spawn a vigorous ecosystem around chronic gastric inflammation, its understanding and its treatment. And we hope that it will inspire other data collaboratives in health — for other chronic inflammations, other forms of cancer or other ailments altogether. PROTO Advanced Personalized Therapies for Osteoarthritis WEBSITE Osteoarthritis (OA) is a chronic progressive joint disorder, characterized by inflammation causing pain, stiffness, swelling and gradual loss of joint function. PROTO aims to halt and partially reverse the structural and functional changes caused by inflammatory processes in OA Our ambitious goal is to introduce: a highly innovative anti-inflammatory local placental derived cell therapy in early-stage OA patients and a personalized sensor-based training intervention intended to prevent inflammation and OA onset during a crucially important ‘window of opportunity’ by correcting pathological movement patterns in pre-stage OA patients. ENDOTARGET Sytemic Endotoxemia as the driver of chronic inflammation–Biomarkers and novel therapeutic targets for Arthritis WEBSITE ENDOTARGET explores the relationship between gut microbiota, gut permeability, and systemic endotoxemia with a special focus on the three most abundant rheumatic diseases (RDs): osteoarthritis, rheumatoid arthritis and spondylarthritis. The aim is to clarify (1) the role of the three factors gut microbiota, gut permeability and systemic endotoxemia in RD onset and pathogenesis, (2) which events and mechanisms are responsible for the origin of RDs, and (3) the influence of the gut microbiota on the joints. Based on the gained knowledge, e.g. new biomarkers for risk assessment will be identified and a Rheumatic disease risk prediction tool (RDPT) will be developed to support clinicians in the classification of patients and to treat RDs preventively. This tool will help to reduce the risk of RD onset and/or to reduce disease activity. PRAESIIDIUM Real-time prediction of the prediabetes risk WEBSITE PRAESIIDIUM will develop a tool based on artificial intelligence coupled with multi-scale, multi-organ integrated mathematical equations for the real-time prediction of the prediabetes risk of an individual. The prediction algorithm will draw on a rich set of information for training, derived from prior clinical data, the individual’s family history, and a pilot study testing wearable sensors that will provide glucose, bioimpedance, and heart rate monitoring. The PRAESIIDIUM platform will be made available to healthcare professionals and patients for an easier data entering and results query and it will be linked to common wearable sensors to monitor the physical activity. PREVALUNG EU Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception WEBSITE The project PREVALUNG EU will harness retrospective and prospective cohorts of both CVD patients and LCDT eligibles to develop actionable biomarkers and validate the four classifiers detecting high-risk individuals before or pre-symptomatic of LC, exploiting the latest advances of system biology omics (metabolomics, metagenomics, immunomics, proteomics, and aging-associated BM stem cell genomics) that correlate with uncontrolled inflammatory status of CVD patients. In particular, using four types of diagnosis tools harnessing either of the four drivers of overt inflammation (metabolism, gut dysbiosis, stem cell mutational status, innate immunity), we shall stratify the CVD patient population and leverage the PLCOm2012 risk score to better identify LC high-risk individuals. We will propose a personalized interceptive measure, whose efficacy will be monitored using PREVALUNG EU Focus Panels. We will robustly validate clinical applications, workflows, and tools for easy and broad adoption of the interceptive system across European public care centers and private stakeholders.

Download needed deliverables for iProlepsis project for psoriatic arthritis. Project deliverables D1.2 Data managmeent plan (initial version) WP1 - Management and coordination Read More D2.3 The iPROLEPSIS trustworthy AI framework WP2 - Knowledge mining, foundation and participatory design Read More D6.1 Project branding and communication channels WP6 - Dissemination, communication and exploitation Read More D2.1 Initial report on user research and co-creation process WP2 - Knowledge mining, foundation and participatory design Read More D4.2 The iPROLEPSIS patient and HCP apps (study version) WP4 - Development of the iPROLEPSIS digital health ecosystem for personalised preventive care Read More D6.2 Dissemination, exploitation and communication plan WP6 - Dissemination, communication and exploitation Read More D2.2 Initial report on the state-of-the-art and datasets WP2 - Knowledge mining, foundation and participatory design Read More D5.1 Study initiation package (iPROLEPSIS-PDPID study) WP5 - Clinical studies Read More D6.3 First report on project visibility and educational material WP6 - Dissemination, communication and exploitation Read More